AU2009268739B2 - 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase - Google Patents

1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Download PDF

Info

Publication number
AU2009268739B2
AU2009268739B2 AU2009268739A AU2009268739A AU2009268739B2 AU 2009268739 B2 AU2009268739 B2 AU 2009268739B2 AU 2009268739 A AU2009268739 A AU 2009268739A AU 2009268739 A AU2009268739 A AU 2009268739A AU 2009268739 B2 AU2009268739 B2 AU 2009268739B2
Authority
AU
Australia
Prior art keywords
amino
compound
oxadiazol
oxadiazole
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009268739A
Other languages
English (en)
Other versions
AU2009268739A1 (en
Inventor
Andrew P. Combs
Qiyan Lin
Pingli Liu
Richard B. Sparks
Lingkai Weng
Eddy W. Yue
Tai-Yuen Yue
Jiacheng Zhou
Wenyu Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Holdings Corp
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41128289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009268739(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of AU2009268739A1 publication Critical patent/AU2009268739A1/en
Application granted granted Critical
Publication of AU2009268739B2 publication Critical patent/AU2009268739B2/en
Priority to AU2014210662A priority Critical patent/AU2014210662A1/en
Assigned to INCYTE HOLDINGS CORPORATION reassignment INCYTE HOLDINGS CORPORATION Request for Assignment Assignors: INCYTE CORPORATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009268739A 2008-07-08 2009-07-07 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Active AU2009268739B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014210662A AU2014210662A1 (en) 2008-07-08 2014-08-08 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7887608P 2008-07-08 2008-07-08
US61/078,876 2008-07-08
US15087309P 2009-02-09 2009-02-09
US61/150,873 2009-02-09
PCT/US2009/049794 WO2010005958A2 (en) 2008-07-08 2009-07-07 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014210662A Division AU2014210662A1 (en) 2008-07-08 2014-08-08 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Publications (2)

Publication Number Publication Date
AU2009268739A1 AU2009268739A1 (en) 2010-01-14
AU2009268739B2 true AU2009268739B2 (en) 2014-05-08

Family

ID=41128289

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2009268739A Active AU2009268739B2 (en) 2008-07-08 2009-07-07 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2014210662A Abandoned AU2014210662A1 (en) 2008-07-08 2014-08-08 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2016204914A Abandoned AU2016204914A1 (en) 2008-07-08 2016-07-13 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2018200457A Ceased AU2018200457A1 (en) 2008-07-08 2018-01-19 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2018267589A Active AU2018267589B2 (en) 2008-07-08 2018-11-20 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2020239772A Active AU2020239772B2 (en) 2008-07-08 2020-09-25 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2014210662A Abandoned AU2014210662A1 (en) 2008-07-08 2014-08-08 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2016204914A Abandoned AU2016204914A1 (en) 2008-07-08 2016-07-13 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2018200457A Ceased AU2018200457A1 (en) 2008-07-08 2018-01-19 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2018267589A Active AU2018267589B2 (en) 2008-07-08 2018-11-20 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
AU2020239772A Active AU2020239772B2 (en) 2008-07-08 2020-09-25 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Country Status (36)

Country Link
US (12) US8088803B2 (enExample)
EP (3) EP3360873A1 (enExample)
JP (2) JP5465720B2 (enExample)
KR (5) KR101847107B1 (enExample)
CN (2) CN102164902B (enExample)
AR (1) AR072490A1 (enExample)
AU (6) AU2009268739B2 (enExample)
BR (2) BR122019015876B8 (enExample)
CA (2) CA3012229C (enExample)
CL (2) CL2009001554A1 (enExample)
CO (1) CO6341622A2 (enExample)
CR (1) CR11871A (enExample)
CY (1) CY1120617T1 (enExample)
DK (2) DK2315756T5 (enExample)
EA (2) EA029781B1 (enExample)
EC (1) ECSP11010798A (enExample)
ES (2) ES2665419T3 (enExample)
HR (2) HRP20141094T1 (enExample)
HU (1) HUE036813T2 (enExample)
IL (2) IL210402A (enExample)
LT (1) LT2824100T (enExample)
ME (1) ME03065B (enExample)
MX (1) MX2011000235A (enExample)
MY (3) MY192633A (enExample)
NO (1) NO2824100T3 (enExample)
NZ (1) NZ590268A (enExample)
PE (1) PE20110308A1 (enExample)
PH (1) PH12014500947B1 (enExample)
PL (2) PL2315756T3 (enExample)
PT (2) PT2824100T (enExample)
RS (2) RS57132B1 (enExample)
SG (2) SG10201805844QA (enExample)
SI (2) SI2315756T1 (enExample)
SM (2) SMT201800206T1 (enExample)
TW (1) TWI453204B (enExample)
WO (1) WO2010005958A2 (enExample)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) * 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
MX2011000235A (es) * 2008-07-08 2011-02-23 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
NO2694640T3 (enExample) 2011-04-15 2018-03-17
ES2903205T3 (es) * 2011-11-09 2022-03-31 Kyowa Kirin Co Ltd Compuestos heterocíclicos que contienen nitrógeno
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2015070007A1 (en) * 2013-11-08 2015-05-14 Incyte Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EP3102237B1 (en) * 2014-02-04 2020-12-02 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
HRP20192285T1 (hr) 2014-03-31 2020-03-06 F. Hoffmann - La Roche Ag Anti-ox40 protutijela i postupci uporabe
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
WO2015188085A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
JP2017520610A (ja) * 2014-07-17 2017-07-27 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ｈｉｖ関連障害を治療するための方法及び組成物
CN105481789B (zh) * 2014-09-15 2020-05-19 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
PL3321265T3 (pl) 2015-03-04 2020-11-16 Gilead Sciences, Inc. Związki 4,6-diamino-pirydo[3,2-d]pirymidynowe i ich wykorzystanie jako modulatorów receptorów toll-podobnych
MX2017011951A (es) * 2015-03-17 2018-06-15 Pfizer Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso.
CN106660974B (zh) * 2015-03-31 2019-08-30 江苏恒瑞医药股份有限公司 含氨磺酰基的1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
BR112017020824A2 (pt) 2015-04-21 2018-07-03 Jiangsu Hengrui Medicine Co., Ltd. derivado de imidazo-isoindol, método de preparação do mesmo e uso médico do mesmo
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
US9891882B2 (en) * 2015-06-01 2018-02-13 Nagravision S.A. Methods and systems for conveying encrypted data to a communication device
AU2016274585A1 (en) 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
MX2017015937A (es) 2015-06-08 2018-12-11 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
JP6654208B2 (ja) * 2015-07-02 2020-02-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤
CA2992238A1 (en) * 2015-07-14 2017-01-19 Kyowa Hakko Kirin Co., Ltd. A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
CN107001271B (zh) * 2015-08-07 2019-05-10 江苏恒瑞医药股份有限公司 羟基脒类衍生物、其制备方法及其在医药上的应用
AU2016312508A1 (en) 2015-08-26 2018-02-15 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN107396498B (zh) 2015-09-14 2019-07-23 昂宝电子（上海）有限公司 用于发光二极管照明系统中的电流调节的系统和方法
CN106565696B (zh) * 2015-10-09 2020-07-28 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
JP2018532756A (ja) * 2015-11-04 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
WO2017080934A1 (en) 2015-11-09 2017-05-18 F. Hoffmann-La Roche Ag Screening assay to identify id01 and/or tdo modulators
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
CN106883193B (zh) * 2015-12-15 2021-10-15 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
TWI654302B (zh) 2016-01-19 2019-03-21 輝瑞股份有限公司 癌症疫苗
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
US11752131B2 (en) 2016-02-19 2023-09-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of obesity
EP3398942B1 (en) * 2016-02-25 2021-01-27 Shenzhen TargetRx, Inc. Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
CN107176933B (zh) * 2016-03-09 2020-10-09 中国科学院上海有机化学研究所 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
BR112018071602B1 (pt) * 2016-04-29 2024-02-27 Iomet Pharma Ltd. Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase
US10696648B2 (en) 2016-05-04 2020-06-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
CN106109472A (zh) * 2016-06-13 2016-11-16 中山大学 氯氮卓作为吲哚胺2,3-双加氧酶-1抑制剂的用途
EP3495354A4 (en) * 2016-08-02 2020-01-15 Shandong Luye Pharmaceutical Co., Ltd. IDO1 INHIBITOR AND PRODUCTION METHOD AND APPLICATION THEREOF
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US20190185439A1 (en) * 2016-08-24 2019-06-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Radiofluorinated carboximidamides as ido targeting pet tracer for cancer imaging
KR20190040990A (ko) * 2016-08-26 2019-04-19 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
CA3037333A1 (en) 2016-09-19 2018-03-22 University Of South Florida Method of targeting oncolytic viruses to tumors
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN110381963A (zh) 2016-10-13 2019-10-25 朱诺治疗学股份有限公司 涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
EP4234691A3 (en) 2016-10-14 2023-10-18 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
CN107954999B (zh) * 2016-10-17 2023-01-24 上海医药集团股份有限公司 含噁二唑环化合物、制备方法、中间体、组合物及应用
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
UY37466A (es) * 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
MX378460B (es) 2016-12-22 2025-03-10 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa.
CN108218807A (zh) * 2016-12-22 2018-06-29 上海长森药业有限公司 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
MX2019008346A (es) 2017-01-13 2019-09-09 Agenus Inc Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
US11173145B2 (en) 2017-01-17 2021-11-16 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
AR110768A1 (es) 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
AU2018243640A1 (en) * 2017-03-29 2019-09-12 Merck Sharp & Dohme Corp. Novel substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
CN108689958B (zh) * 2017-04-05 2021-09-17 南京华威医药科技集团有限公司 一种含有肼基的吲哚胺2,3-双加氧化酶抑制剂
CN106967005B (zh) * 2017-04-07 2019-07-16 上海肇钰医药科技有限公司 一种能抑制ido的化合物、其制备方法及其用途
TWI842672B (zh) 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN108794423B (zh) * 2017-04-27 2022-07-19 鲁南制药集团股份有限公司 亚氨脲衍生物
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
CN109081818B (zh) * 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN109111438B (zh) * 2017-06-26 2021-11-02 正大天晴药业集团股份有限公司 用于ido抑制剂的脒类化合物
CA3069363A1 (en) 2017-07-11 2019-01-17 Pfizer Inc. Immunogenic compositions comprising cea muc1 and tert
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
TW201920202A (zh) 2017-08-17 2019-06-01 瑞士商愛杜西亞製藥有限公司 吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
CN107311956A (zh) * 2017-08-22 2017-11-03 合肥圣迪利克医药科技有限公司 一种艾卡跺司他合成方法
SG11202001319QA (en) 2017-09-04 2020-03-30 Agenus Inc T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
CN108863976B (zh) * 2017-09-11 2022-09-16 郑州泰基鸿诺医药股份有限公司 用作ido调节剂的化合物及其应用
WO2019055786A1 (en) 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2019057104A1 (zh) * 2017-09-20 2019-03-28 上海翰森生物医药科技有限公司 一种双加氧酶抑制剂的盐及其制备方法和用途
CN109897011B (zh) * 2017-12-08 2023-10-31 上海华汇拓医药科技有限公司 一类ido抑制剂及其应用
CN109928922A (zh) * 2017-12-18 2019-06-25 成都华健未来科技有限公司 一类环己烷类化合物
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
CN109942565B (zh) * 2017-12-20 2021-03-26 海创药业股份有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
CN111601810A (zh) 2018-01-15 2020-08-28 爱杜西亚药品有限公司 吲哚胺2,3-双加氧酶和/或色氨酸2,3-双加氧酶的抑制剂
CN108586378B (zh) 2018-01-22 2020-06-19 南京华威医药科技集团有限公司 吲哚胺2,3-双加氧化酶抑制剂及其制备方法和用途
GB2585149B (en) * 2018-01-24 2022-06-01 Nanjing Carephar Shenghui Pharmaceutical Co Ltd Modulator of indoleamine-(2.3)-dioxygenase, preparation method and use thereof
CN110577501A (zh) * 2018-06-07 2019-12-17 江苏柯菲平医药股份有限公司 吲哚胺2,3-双加氧酶调节剂，其制备方法及用途
CN110066253B (zh) * 2018-01-24 2023-06-23 江苏柯菲平医药股份有限公司 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用
CN110128367A (zh) * 2018-02-02 2019-08-16 成都海创药业有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN108101899B (zh) * 2018-02-11 2021-01-26 中国药科大学 IDO1抑制剂Epacadostat中间体的制备方法
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20190314324A1 (en) 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110407765B (zh) * 2018-04-28 2022-12-06 上海挚盟医药科技有限公司 1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
GB201809050D0 (en) 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN109180603A (zh) * 2018-10-10 2019-01-11 中国药科大学 Epacadostat关键中间体的制备方法
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
CN111617078B (zh) * 2019-02-28 2023-02-03 四川科伦博泰生物医药股份有限公司 用于疾病治疗和/或预防的药物组合物、方法及其用途
US12318403B2 (en) 2019-03-07 2025-06-03 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides and prodrugs thereof
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
KR20220042352A (ko) 2019-07-03 2022-04-05 아토사 테라퓨틱스, 인크. 엔독시펜의 서방성 조성물
CN110204537B (zh) * 2019-07-10 2021-10-08 盛世泰科生物医药技术(苏州)有限公司 一种用作吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑衍生物
WO2021005222A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4007602A1 (en) 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
TWI755055B (zh) * 2019-09-18 2022-02-11 台灣神隆股份有限公司 用於製備惡拉戈利鈉及其中間體的方法
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
EP4069729B1 (en) 2019-12-06 2025-01-22 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US20230303599A1 (en) 2020-08-07 2023-09-28 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022064526A1 (en) * 2020-09-25 2022-03-31 Msn Laboratories Private Limited, R&D Center Solid state forms of epacadostat and their processes for preparation thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
CN119841748B (zh) * 2025-03-21 2025-06-10 济南大学 一种对甲苯磺酰脲的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258719A1 (en) * 2005-05-10 2006-11-16 Combs Andrew P Modulators of indoleamine 2,3-dioxygenase and methods of using the same

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (enExample) 1973-09-05 1981-05-16
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
DD128918A5 (de) 1975-09-11 1977-12-21 Philagro Sa Phythohormonale und herbizide zusammensetzungen
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4323681A (en) 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58208275A (ja) 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
DE3462259D1 (de) 1983-07-22 1987-03-05 Bayer Ag Substituted furazans
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS6320710A (ja) 1986-07-11 1988-01-28 Matsushita Electric Ind Co Ltd 薄膜磁気ヘツドの製造方法
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JP2696342B2 (ja) 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
DE68901424D1 (de) 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP2709677B2 (ja) 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
SI9200344B (sl) 1992-11-26 1998-06-30 Lek, Postopek za pripravo amlodipin benzensulfonata
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
PL326353A1 (en) 1995-10-17 1998-09-14 Astra Pharma Prod Pharmaceutically active quinozolinic compounds
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
RO121119B1 (ro) 1997-12-10 2006-12-29 Dainippon Ink And Chemicals, Inc. Derivaţi de oximă şi chimicale pentru agricultură, incluzând aceşti derivaţi
CN1131863C (zh) 1998-06-02 2003-12-24 住化武田农药株式会社 噁二唑啉衍生物及其作为杀虫剂的用途
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
EP1075469B1 (en) 1999-03-03 2004-05-26 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US7144902B1 (en) 1999-04-09 2006-12-05 Abbott Gmbh & Co. Kg Prodrugs of thrombin inhibitors
KR100882544B1 (ko) 1999-05-24 2009-02-12 미쓰비시 타나베 파마 코퍼레이션 페녹시프로필아민 화합물
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
ES2293980T3 (es) 2000-01-13 2008-04-01 Amgen Inc. Agentes antibacterianos.
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
KR100819668B1 (ko) * 2000-12-18 2008-04-04 액테리온 파마슈티칼 리미티드 신규한 피리미딘-설퍼아마이드
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
AU2002319237B2 (en) 2001-06-18 2008-01-03 Merck Serono Sa Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
US7973031B2 (en) 2001-10-30 2011-07-05 Novartis Ag Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
CN101001857B (zh) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
ATE353013T1 (de) 2002-02-19 2007-02-15 Pfizer Italia Srl Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
CN1312154C (zh) * 2002-03-05 2007-04-25 伊莱利利公司 作为激酶抑制剂的嘌呤衍生物
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
EP2177601A1 (en) 2002-04-12 2010-04-21 Medical College of Georgia Research Institute, Inc Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
PL372246A1 (en) 2002-05-28 2005-07-11 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
JP2007512230A (ja) 2003-08-20 2007-05-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
BRPI0511978A (pt) 2004-06-10 2008-01-22 Irm Llc compostos e composições como inibidores de proteìnas quinases
JP4970946B2 (ja) 2004-09-08 2012-07-11 田辺三菱製薬株式会社 モルホリン化合物
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
JP2008544818A (ja) 2005-06-30 2008-12-11 アントフロゲネシス コーポレーション 胎盤由来コラーゲンバイオ線維を用いた鼓膜の修復
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
WO2007095050A2 (en) 2006-02-09 2007-08-23 Incyte Corporation N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US20080119491A1 (en) 2006-09-19 2008-05-22 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2011000235A (es) 2008-07-08 2011-02-23 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
LT2632467T (lt) 2010-10-25 2016-09-12 G1 Therapeutics, Inc. Cdk inhibitoriai
PH12013501940A1 (en) 2011-03-23 2015-12-04 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2015070007A1 (en) 2013-11-08 2015-05-14 Incyte Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EP3102237B1 (en) 2014-02-04 2020-12-02 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
JP2018532756A (ja) 2015-11-04 2018-11-08 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ インドールアミン２，３−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
JP2018020710A (ja) 2016-08-05 2018-02-08 三井造船株式会社 船舶用舵及び船舶
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
EP4007602A1 (en) 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258719A1 (en) * 2005-05-10 2006-11-16 Combs Andrew P Modulators of indoleamine 2,3-dioxygenase and methods of using the same

Also Published As

Publication number Publication date
EP3360873A1 (en) 2018-08-15
CN104042611B (zh) 2019-05-14
SI2315756T1 (sl) 2014-12-31
BRPI0915692B8 (pt) 2021-05-25
HRP20180662T1 (hr) 2018-06-01
PH12014500947B1 (en) 2019-03-01
JP2011527686A (ja) 2011-11-04
AU2018267589B2 (en) 2020-06-25
IL210402A0 (en) 2011-03-31
KR20160110969A (ko) 2016-09-23
US20120058079A1 (en) 2012-03-08
DK2824100T3 (en) 2018-04-16
NO2824100T3 (enExample) 2018-07-21
WO2010005958A2 (en) 2010-01-14
EA022669B1 (ru) 2016-02-29
US10034864B2 (en) 2018-07-31
US20190298700A1 (en) 2019-10-03
CA2743975C (en) 2018-09-11
PE20110308A1 (es) 2011-06-10
US20160220543A1 (en) 2016-08-04
KR20180133538A (ko) 2018-12-14
CR11871A (es) 2011-03-30
IL235870A (en) 2016-05-31
KR20180037325A (ko) 2018-04-11
ES2665419T3 (es) 2018-04-25
AU2016204914A1 (en) 2016-08-04
CA3012229A1 (en) 2010-01-14
BR122019015876B8 (pt) 2021-07-27
US20170348289A1 (en) 2017-12-07
CA3012229C (en) 2020-11-10
US20220331296A1 (en) 2022-10-20
US20180177769A1 (en) 2018-06-28
JP5819451B2 (ja) 2015-11-24
KR101783004B1 (ko) 2017-09-28
EP2824100B1 (en) 2018-02-21
KR20110031971A (ko) 2011-03-29
HK1206029A1 (en) 2015-12-31
AU2018200457A1 (en) 2018-02-08
KR101649548B1 (ko) 2016-08-19
NZ590268A (en) 2012-11-30
JP2014114299A (ja) 2014-06-26
US20150190378A1 (en) 2015-07-09
CO6341622A2 (es) 2011-11-21
IL235870A0 (en) 2015-01-29
CY1120617T1 (el) 2019-12-11
DK2315756T3 (da) 2014-10-13
KR20170113707A (ko) 2017-10-12
KR101927291B1 (ko) 2018-12-10
JP5465720B2 (ja) 2014-04-09
CA2743975A1 (en) 2010-01-14
US8993605B2 (en) 2015-03-31
SG192485A1 (en) 2013-08-30
SI2824100T1 (en) 2018-06-29
BRPI0915692B1 (pt) 2019-12-03
AU2018267589A1 (en) 2018-12-06
US8822511B2 (en) 2014-09-02
US9320732B2 (en) 2016-04-26
US20210030722A1 (en) 2021-02-04
US10653677B2 (en) 2020-05-19
AU2014210662A1 (en) 2014-08-28
MY171866A (en) 2019-11-05
PT2315756E (pt) 2014-12-16
ME03065B (me) 2019-01-20
US20240173303A1 (en) 2024-05-30
MY177058A (en) 2020-09-03
US11207302B2 (en) 2021-12-28
HUE036813T2 (hu) 2018-07-30
CN102164902A (zh) 2011-08-24
SMT201800206T1 (it) 2018-05-02
WO2010005958A3 (en) 2010-06-24
CN102164902B (zh) 2014-07-23
LT2824100T (lt) 2018-05-10
MY192633A (en) 2022-08-29
ES2524266T9 (es) 2015-10-05
PT2824100T (pt) 2018-05-10
HK1157692A1 (en) 2012-07-06
EP2315756A2 (en) 2011-05-04
EA201170161A1 (ru) 2011-08-30
SMT201400179B (it) 2015-01-15
TW201006827A (en) 2010-02-16
AU2020239772A1 (en) 2020-10-22
KR102031538B1 (ko) 2019-11-08
KR101847107B1 (ko) 2018-04-10
PH12014500947A1 (en) 2015-03-30
AR072490A1 (es) 2010-09-01
DK2315756T5 (en) 2015-08-03
BR122019015876B1 (pt) 2020-03-10
ECSP11010798A (es) 2011-03-31
EP2315756B9 (en) 2015-07-22
EA029781B1 (ru) 2018-05-31
CL2009001554A1 (es) 2009-10-30
ES2524266T3 (es) 2014-12-04
AU2009268739A1 (en) 2010-01-14
EA201500530A1 (ru) 2015-08-31
HRP20141094T1 (hr) 2015-01-16
EP2824100A1 (en) 2015-01-14
RS53688B9 (sr) 2020-01-31
US10369137B2 (en) 2019-08-06
US20100015178A1 (en) 2010-01-21
US20140023663A1 (en) 2014-01-23
PL2824100T3 (pl) 2018-07-31
RS53688B1 (sr) 2015-04-30
US8796319B2 (en) 2014-08-05
CN104042611A (zh) 2014-09-17
AU2020239772B2 (en) 2022-09-15
EP2315756B1 (en) 2014-09-03
MX2011000235A (es) 2011-02-23
SG10201805844QA (en) 2018-08-30
PL2315756T3 (pl) 2015-02-27
US20140315962A1 (en) 2014-10-23
US8088803B2 (en) 2012-01-03
IL210402A (en) 2015-02-26
TWI453204B (zh) 2014-09-21
RS57132B1 (sr) 2018-07-31
US9789094B2 (en) 2017-10-17
CL2014000363A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
AU2020239772B2 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
HK1259687A1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
HK1206029B (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
HK1157692B (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INCYTE HOLDINGS CORPORATION

Free format text: FORMER OWNER WAS: INCYTE CORPORATION